Lamivudine/nevirapine/zidovudine tablets - Hetero Drugs

Drug Profile

Lamivudine/nevirapine/zidovudine tablets - Hetero Drugs

Alternative Names: Lamivudine/zidovudine/nevirapine tablets - Hetero Drugs; Nevirapine/lamivudine/zidovudine tablets - Hetero Drugs; Nevirapine/zidovudine/lamivudine tablets - Hetero Drugs; Zidovudine/lamivudine/nevirapine tablets - Hetero Drugs; Zidovudine/nevirapine/lamivudine tablets - Hetero Drugs

Latest Information Update: 13 Jul 2015

Price : $50

At a glance

  • Originator Hetero Drugs
  • Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Azides; Cyclopropanes; Dideoxynucleosides; Nucleosides; Pyridines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top